WINDTREE THERAPEUTICS INC (WINT)

US97382D4025 - Common Stock

0.354  -0.01 (-3.78%)

After market: 0.368 +0.01 (+3.95%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

WINDTREE THERAPEUTICS INC

NASDAQ:WINT (3/28/2024, 8:00:02 PM)

After market: 0.368 +0.01 (+3.95%)

0.354

-0.01 (-3.78%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap3.25M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

WINT Daily chart

Company Profile

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 20 full-time employees. The firm is focused on the development of therapeutics intended to address unmet medical needs in important cardiovascular care markets. The Company’s development programs are primarily focused on the treatment of cardiovascular diseases. Its lead product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients to treat early cardiogenic shock and acute heart failure (AHF). Its Rostafuroxin is an investigational drug product candidate being developed for the treatment of hypertension in patients with a specific genetic profile. Its heart failure cardiovascular portfolio also includes sarco endoplasmic reticulum Ca2+ -ATPase 2a (SERCA2a) activators. The firm is also conducting early exploratory research to assess potential product candidates, including oral and intravenous SERCA2a activator heart failure compounds.

Company Info

WINDTREE THERAPEUTICS INC

2600 Kelly Rd Ste 100

Warrington PENNSYLVANIA 18976

P: 12154889300

CEO: Craig E. Fraser

Employees: 20

Website: https://windtreetx.com/

WINT News

News Imagea month ago - Seeking AlphaWindtree Therapeutics files to sell 608,272 shares for holders (NASDAQ:WINT)

Windtree Therapeutics files prospectus for resale of 608,272 shares of common stock by selling holders. Not an offer to sell.

News Image2 months ago - Windtree TherapeuticsWindtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

WARRINGTON, Pa., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...

News Image2 months ago - Windtree TherapeuticsWindtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives

WARRINGTON, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...

News Image2 months ago - Windtree TherapeuticsWindtree Eliminates $15 Million Contingent Liability to Deerfield Management Company

WARRINGTON, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...

News Image2 months ago - Windtree TherapeuticsWindtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region

Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for all development, manufacturing,...

News Image3 months ago - Windtree TherapeuticsWindtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator

The new preclinical data further supports istaroxime clinical data from three Phase 2 studies Arrythmias can be a serious complication of current rescue...

WINT Twits

Here you can normally see the latest stock twits on WINT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example